Add BrightSurf on Google Email

Lung cancer rewires immune cells in the bone marrow to weaken body’s defenses

Researchers found that lung tumors reshape immune cells in the bone marrow before they reach the cancer, altering their function and leading to a stronger anti-cancer response. The study identified NRF2 as a key protein involved in this process and proposed blocking it as a potential strategy to enhance immunotherapy.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNature·TypeExperimental study·DateSep 10, 2025

A stunning first look at the viruses inside us

Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.

SourceLa Jolla Institute for Immunology·JournalScience Advances·TypeExperimental study·DateAug 27, 2025

Study advances understanding of rare type of lung cancer

A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...

SourceUniversity of Oklahoma·JournalNature Communications·TypeData/statistical analysis·DateAug 20, 2025

Resolving the structural basis of therapeutic antibody function in cancer immunotherapy

A team of researchers has visualized the nanoscale architecture of CD20 receptors and their interactions with anti-CD20 antibodies using a novel super-resolution microscopy technique. The study reveals that structural changes in antibody design translate into different receptor patterns and cellular responses, opening up new pathways f...

SourceLudwig-Maximilians-Universität München·JournalNature Communications·DateAug 11, 2025

Shedding light on why immunotherapy sometimes fails

Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.

SourceChiba University·JournalInternational Journal of Pharmaceutics·TypeExperimental study·DateJul 24, 2025

Giving T cells a break: controlled physical barrier created to boost cancer immunotherapy

Researchers developed a biomimetic physical barrier that temporarily blocks T cell-tumor cell interactions, delaying exhaustion and enabling a stronger immune response. The breakthrough strategy can potentially be combined with other immunotherapeutic approaches to enhance treatment efficacy.

SourceChinese Academy of Sciences Headquarters·JournalProceedings of the National Academy of Sciences·DateJul 16, 2025

Good prognosis for men with prostate cancer treated according to guidelines

A new study from Uppsala University found that most men with prostate cancer who receive recommended treatment have a good prognosis, with a lower risk of dying from prostate cancer than other causes. The study's findings highlight the importance of assessing a patient's life expectancy in choosing an appropriate treatment strategy.

SourceUppsala University·JournalJournal of the National Comprehensive Cancer Network·TypeObservational study·DateJul 14, 2025

Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later

A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal of Clinical Oncology·DateJul 10, 2025

Longitudinal study sets new survival benchmark for patients with advanced biliary tract cancer

A new study published in the Journal of Hepatology shows that durvalumab plus GemCis significantly improves overall survival for patients with advanced biliary tract cancer. The three-year follow-up analysis found that over twice as many participants treated with durvalumab plus GemCis remained alive compared to those treated with a pl...

SourceElsevier·JournalJournal of Hepatology·TypeRandomized controlled/clinical trial·DateJul 10, 2025

A new cell therapy for leukaemia shows high efficacy and safety in the laboratory

A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.

SourceJosep Carreras Leukaemia Research Institute·JournalJournal of Hematology & Oncology·TypeExperimental study·DateJul 7, 2025

Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study

This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.

SourceNational Center for Respiratory Medicine·JournalJournal of Thoracic Disease·TypeObservational study·DateJun 28, 2025

Cancer immunotherapy shows promise for transplant patients

A new study reveals that cancer-fighting immunotherapy drugs may offer benefits to organ transplant recipients with advanced cancer when carefully managed. The study found that about one in three patients responded positively to treatment within a year, with improved survival outcomes comparable to the general population.

SourceFlinders University·JournalJAMA Oncology·TypeSystematic review·DateJun 24, 2025

Official BRACELET-1 trial results indicate that adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in HR+ HER2- metastatic breast cancer

The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.

SourcePrECOG, LLC·JournalClinical Cancer Research·TypeRandomized controlled/clinical trial·DateJun 24, 2025

Sudy shows that existing drug class may help patients with skin cancer that resists standard treatments

Researchers at NYU Langone Health discovered that a specific biological pathway explains why many patients with deadly melanoma do not respond to latest cancer treatments. The study found therapeutic targets that could limit melanoma growth in patients with NF1 mutations, suggesting a novel approach for treatment.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalCancer Research·TypeExperimental study·DateJun 10, 2025

MET mutation and cancer immunity

A recent study found that MET mutations are associated with enhanced tumor immunogenicity, increased immune cell infiltration, and improved response rates to immune checkpoint blockade. Certain single base substitutions identified as robust predictive biomarkers for survival in pan-cancer immunotherapy.

SourceCompuscript Ltd·JournalGenes & Diseases·DateJun 5, 2025

Immunotherapy before surgery improves lung cancer survival in global clinical trial led by Irish cancer specialist

A global clinical trial led by Irish cancer specialist Prof. Patrick Forde shows that immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long-term survival. The study found that patients who received immunotherapy plus chemotherapy had improved outcomes compared to those who rec...

SourceTrinity College Dublin·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJun 2, 2025

Adding immune checkpoint inhibitor to standard chemotherapy regimen improves outcomes in stage 3 colon cancer, study finds

A phase 3 trial of patients with surgically resected stage 3 dMMR colon cancer found that adding an immune checkpoint inhibitor (atezolizumab) to standard chemotherapy improved disease-free survival by 50% compared to chemotherapy alone. The study results provide new evidence for a treatment approach in this high-risk patient population.

Transforming immunotherapy design

Assistant professor of electrical and computer engineering Natasa Miskov-Zivanov is receiving a $581,503 NSF CAREER Award for her project that leverages AI to design more effective lymphocytes for cancer immunotherapies. The system aims to accelerate the process of designing new therapeutic cell designs.

Stratifying the immune landscape of tongue cancer

Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.

SourceInstitute of Science Tokyo·JournalCancer Immunology Immunotherapy·TypeExperimental study·DateMay 27, 2025